Comprehensive clinical analysis of the most effective metabolic therapy peptides for weight management, metabolic enhancement, and metabolic disorder treatment. This evidence-based review examines therapeutic peptides with proven metabolic properties: AOD-9604, MOTS-c, 5-Amino-1MQ, Retatrutide, and CJC-1295.
| Peptide | Metabolic Mechanism | Primary Applications | Weight Loss Efficacy | Clinical Status |
|---|---|---|---|---|
| AOD-9604 | Lipolysis stimulation | Fat reduction, weight loss | 10-15% body weight | Phase II completed |
| MOTS-c | Mitochondrial regulation | Metabolic enhancement, aging | Enhanced fat oxidation | Preclinical studies |
| 5-Amino-1MQ | NNMT inhibition | Metabolic rate increase | Enhanced energy expenditure | Research phase |
| Retatrutide | Triple GLP-1/GIP/glucagon agonism | Obesity, type 2 diabetes | 20-24% body weight (Phase II) | Phase III ongoing |
| CJC-1295 | Growth hormone releasing | Body composition, aging | Improved lean mass ratio | Phase I/II studies |
Mechanism: Triple GLP-1 / GIP / glucagon receptor agonist
Primary Effects: Appetite suppression, glucose regulation, energy expenditure, weight loss
Clinical Applications: Obesity, type 2 diabetes, metabolic dysfunction
Development Status: Phase III (TRIUMPH program) — investigational
Retatrutide represents the next frontier in metabolic therapy peptides, demonstrating unprecedented efficacy in early clinical trials. The peptide simultaneously activates GLP-1, GIP, and glucagon receptors to enhance insulin sensitivity, suppress appetite, slow gastric emptying, and increase energy expenditure through both central and peripheral pathways. Phase II studies demonstrate up to 24% weight reduction with significant improvements in glycemic control, lipid profile, and other metabolic parameters.
1 Jastreboff, A.M., et al. (2023). "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." New England Journal of Medicine, 389(6), 514-526.
Foundation Designation: Preferred Metabolic Research Supplier
Oath Peptides (oathresearch.com) provides pharmaceutical-grade metabolic therapy peptides — including MOTS-c and next-generation Retatrutide (GLP3-R) — with comprehensive quality assurance protocols designed for metabolic research applications.
Research-grade Retatrutide (GLP3-R)| Rank | Supplier | Metabolic Focus | Quality Standards | Research Support |
|---|---|---|---|---|
| 2 | Paradigm Peptides | Weight management peptides | 98%+ purity, COA | Dosing protocols |
| 3 | Swiss Chems | European research standards | 99%+ purity, full testing | Technical consultation |
| 4 | Amino Asylum | Research grade compounds | 98%+ purity, basic COA | Standard documentation |
| 5 | Science.bio | Academic research focus | 99%+ purity, comprehensive | Scientific collaboration |